STOCK TITAN

I-MAB American Depositary Shares - IMAB STOCK NEWS

Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.

I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.

The company’s pipeline includes several promising candidates:

  • Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
  • Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
  • Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
  • Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
  • Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).

I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.

Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.

For the latest updates and detailed information, visit the official website at I-Mab Biopharma.

News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced two poster presentations showcasing data on lemzoparlimab at the 64th ASH Annual Meeting from December 10-13, 2022, in New Orleans. The presentations will cover biomarker analyses from a phase 2 study involving lemzoparlimab and azacitidine for myelodysplastic syndrome and preclinical data on leveraging CD47 and CD38 immuno-oncology targets for multiple myeloma treatment. The research indicates potential clinical benefits and therapeutic mechanisms, especially in high-risk populations, underscoring I-Mab's commitment to advancing lemzoparlimab's clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced new preclinical data for its assets lemzoparlimab and uliledlimab, to be presented at the 37th SITC Annual Meeting in Boston from November 8-12, 2022. The presentations will include enhanced activity against HER2 expressing tumors and novel immune modulatory mechanisms of uliledlimab. Abstracts will be available on the SITC website on November 7, 2022. I-Mab continues its commitment to developing innovative biologics for cancer therapies and has multiple ongoing clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced the successful completion of an End-of-Phase 2 meeting with China's National Medical Products Administration (NMPA), leading to approval for a Phase 3 trial of lemzoparlimab combined with azacitidine for higher-risk myelodysplastic syndrome (HR-MDS). The encouraging Phase 2 results, presented at ESMO Congress 2022, showed that the combination therapy was effective and safe. The company aims to submit a biologic license application in China following this trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
-
Rhea-AI Summary

I-Mab announced positive results from its Phase 2 clinical trial of lemzoparlimab combined with azacitidine (AZA) for treating higher-risk myelodysplastic syndrome (HR-MDS) at the ESMO Congress 2022. The overall response rate (ORR) was 86.7% for patients treated over 6 months, while the complete response (CR) rate reached 40%. Notably, lemzoparlimab did not require priming dosing and exhibited no unexpected safety signals. A Phase 3 trial is planned to further evaluate this promising combination therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

I-Mab announced that the Phase 2 clinical trial results of lemzoparlimab, in combination with azacitidine, will be presented at the ESMO Congress 2022 on September 10. This presentation will feature initial results regarding the drug's efficacy for patients with higher risk myelodysplastic syndrome (HR-MDS). Additionally, an investor conference call is scheduled for September 12 at 8:00 a.m. ET to discuss the data in detail.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced significant clinical achievements and financial results for the first half of 2022. Key milestones include positive data for lemzoparlimab, uliledlimab, and TJ-CD4B, with lemzoparlimab on track for a Phase 3 study targeting MDS. The partnership with AbbVie could yield up to $1.295 billion in milestone payments. With a robust cash position of $586 million, I-Mab is well-positioned to fund operations for over three years. The company plans to submit three BLAs by 2024, focusing on five key assets that drive its business strategy towards commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced on August 23, 2022, its plan to implement a share repurchase program authorized by its Board of Directors. The Company and senior management, including Chairman Dr. Jingwu Zang, intend to use personal funds to buy up to US$40 million of the Company's American Depositary Shares (ADSs) on the open market. The timing and amount of repurchases will comply with U.S. Securities and Exchange Commission regulations. This move aims to enhance shareholder value as I-Mab progresses in its mission to develop innovative biologics for immuno-oncology diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
none
Rhea-AI Summary

I-Mab, a clinical-stage biopharmaceutical company, will report its business and financial results for the six months ending June 30, 2022, on August 30, 2022. The updates will cover global clinical development of key assets, upcoming milestones, and potential share purchase programs. Conference calls are scheduled on the same day, at 7:00 a.m. ET for Mandarin and 8:15 a.m. ET for English. I-Mab aims to deliver innovative biologics for immuno-oncology diseases and has over 20 clinical and preclinical-stage drug candidates in its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences earnings

FAQ

What is the current stock price of I-MAB American Depositary Shares (IMAB)?

The current stock price of I-MAB American Depositary Shares (IMAB) is $0.923 as of December 20, 2024.

What is the market cap of I-MAB American Depositary Shares (IMAB)?

The market cap of I-MAB American Depositary Shares (IMAB) is approximately 76.3M.

What is I-Mab's core focus?

I-Mab focuses on discovering, developing, and commercializing novel and highly differentiated biologics to treat cancers and autoimmune disorders.

What are some key products in I-Mab's pipeline?

Key products include felzartamab, eftansomatropin, olamkicept, enoblituzumab, and efineptakin.

Where are I-Mab's main operations located?

I-Mab operates primarily from Rockville, Maryland, and San Diego, California.

What recent strategic move has I-Mab made?

I-Mab has divested its Chinese assets and operations to focus more on the U.S. and international markets.

What is felzartamab?

Felzartamab (TJ202) is a CD38 antibody in Phase III trials aimed at treating multiple myeloma and autoimmune diseases.

Who is I-Mab collaborating with on givastomig?

I-Mab is collaborating with Bristol Myers Squibb to study givastomig in combination with nivolumab and chemotherapy for advanced gastric and esophageal cancers.

How does I-Mab fund its operations and research?

I-Mab funds its operations through partnerships, strategic collaborations, and equity investments. Recent strategic divestitures also support its financial health.

What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?

The FDA's Breakthrough Therapy designation for felzartamab recognizes its potential to significantly improve treatment for primary membranous nephropathy and other immune-mediated diseases.

What is I-Mab's approach to drug development?

I-Mab employs Fast-to-Proof-of-Concept and Fast-to-Market strategies, leveraging internal R&D and global partnerships to expedite drug development.

How can investors stay updated on I-Mab's progress?

Investors can stay updated by visiting I-Mab's official website, following their social media channels, and accessing their annual reports and press releases.

I-MAB American Depositary Shares

Nasdaq:IMAB

IMAB Rankings

IMAB Stock Data

76.29M
62.31M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville